Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Candel Therapeutics

Summary

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

History

Founded in 2003, Candel Therapeutics is a privately held biopharmaceutical company dedicated to developing innovative therapeutics for inflammatory diseases with high medical needs. The company has leveraged its scientist-driven approach and powerful drug discovery platform to create an extensive pipeline of next-generation biotherapeutics targeting pathways to inflammation and other biological processes.

Mission

Candel Therapeutics is committed to improving treatments for patients suffering from autoimmune and inflammatory diseases by identifying and developing innovative, cutting-edge therapeutics that address unmet medical needs.

Vision

Candel Therapeutics' vision is to offer the best cutting-edge treatments for diseases associated with inflammation and autoimmune disorders to improve the lives of those affected.

References

https://in.investing.com/equities/candel-therapeutics

https://finance.yahoo.com/quote/CADL/profile?p=CADL

https://www.crunchbase.com/organization/advantagene

https://www.candeltx.com

Leadership team

Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. (Founder & Director)

Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. (Pres, CEO & Director)

Ms. Carrie Smith Cox (Special Advisor to the CEO)

Products / Services

Biotechnology, Genetics, Health Care, Health Diagnostics, Medical, Therapeutics

Number of Employees

50 - 100

Address

Needham, Massachusetts, United States

Established

1999-01-01

Company Registration

SEC CIK number: 0001841387

Traded as

NASDAQ:CADL

Website

https://www.candeltx.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Candel Therapeutics

Summary

History

Mission

Vision

Candel Therapeutics' vision is to offer the best cutting-edge treatments for diseases associated with inflammation and autoimmune disorders to improve the lives of those affected.

References

https://in.investing.com/equities/candel-therapeutics

https://finance.yahoo.com/quote/CADL/profile?p=CADL

https://www.crunchbase.com/organization/advantagene

https://www.candeltx.com

Leadership team

Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. (Founder & Director)

Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. (Pres, CEO & Director)

Ms. Carrie Smith Cox (Special Advisor to the CEO)

Products / Services

Biotechnology, Genetics, Health Care, Health Diagnostics, Medical, Therapeutics

Number of Employees

50 - 100

Address

Needham, Massachusetts, United States

Established

1999-01-01

Company Registration

SEC CIK number: 0001841387

Traded as

NASDAQ:CADL

Website

https://www.candeltx.com

Social Media

Last Updated: 2026

Candel Therapeutics

Share

Contacts

Follow Us

Candel Therapeutics

Share

Contacts

Follow Us